Benzinga | Apr 14, 2021 08:05AM EDT

PTC Therapeutics Launches PTC Pinpoint Direct Program For Patient-Initiated Genetic Testing

PTC Therapeutics, Inc. (NASDAQ:PTCT) today introduced a new no-charge, patient-initiated testing program in the United States for individuals who have symptoms consistent with, or a diagnosis of, cerebral palsy (CP) with no evidence of brain injury.